If a child struggles with big emotions and anxiety, could it actually be untreated ADHD?
Starting ADHD medication before age 13 may physically protect the developing brain from future psychiatric disorders.
* Redefining profound autism without IQ scores
* Gene-editing tools that un-silence rare genetic variants
* ADHD's evolution from focus issues to emotional regulation
* Systemic misdiagnosis and masking in the Black community
We explore why the federal government is stalling on its strategic funding plan just as science reaches a genetic turning point.
----------------------------------------
Today’s selection covers critical shifts in federal autism policy, breakthroughs in genetic medicine, and new research into the long-term benefits of early ADHD intervention (Blog Name: Living on the Spectrum).
FEDERAL AUTISM MEETING RAISES CONCERNS OVER RESEARCH PRIORITIES [https://www.thetransmitter.org/spectrum/slightly-unhinged-federal-autism-meeting-portends-unclear-research-priorities/?utm_source=The+Transmitter+newsletters&utm_campaign=9182ba8d74-DAILY+20260507+THURSDAY+%28IACC+UNCERTAINTY%29&utm_medium=email&utm_term=0_-434a84391f-448958045]
STRATEGY AND FUNDING RISKS
The Interagency Autism Coordinating Committee (IACC) recently met without developing a mandatory strategic plan for research, as required by the Autism CARES Act. This failure to set clear research priorities could lead to a lapse in federal funding. Rather than finalizing a research strategy, the committee focused on policy proposals regarding medical comorbidities and wandering.
CONTENTIOUS POLICY DISCUSSIONS
The meeting included debates over a revised definition of "profound autism" that omits IQ scores. Some participants promoted therapies with weak evidence bases, including microbiome research and facilitated communication. Sylvia Fogel, IACC chair, defended these focus areas as addressing urgent family concerns and stated the committee’s role includes advising the government on policy, not just research.
PROCEDURAL OBJECTIONS
Advocacy groups, such as the Autistic Self Advocacy Network (ASAN) and the Autism Science Foundation, cited procedural violations and a lack of transparency during the session. Critics expressed concern that moving away from a research-focused agenda diminishes the committee's effectiveness in guiding federal scientific investment.
NEW FRONTIERS IN GENETIC MEDICINE FOR AUTISM [https://www.thetransmitter.org/spectrum/advances-in-genetic-medicine-took-center-stage-at-insar/?utm_source=The+Transmitter+newsletters&utm_campaign=9182ba8d74-DAILY+20260507+THURSDAY+%28IACC+UNCERTAINTY%29&utm_medium=email&utm_term=0_-434a84391f-448958045]
TARGETED GENETIC APPROACHES
Researchers at the 2026 International Society for Autism Research (INSAR) meeting detailed progress in addressing rare genetic variants including SCN2A, SHANK3, and UBE3A. The field is moving toward using CRISPR and epigenome editing to modify how genes are expressed without permanently altering the underlying DNA code.
CLINICAL TRIAL PROGRESS
Trials for Angelman syndrome demonstrated that antisense oligonucleotides (ASOs) can successfully "un-silence" the UBE3A gene. These trials reported measurable improvements in cognition, speech, and independence across different age groups. The FDA’s Plausible Mechanism Framework is currently helping to speed the development of these treatments for ultra-rare conditions.
DELIVERY INNOVATION
Discussion at the conference highlighted new methods for delivering genetic therapies, including viral vectors and nanoparticles designed to cross the blood-brain barrier. These delivery systems offer potential pathways for future therapies targeting language and adaptive functioning, even for families where a specific genetic cause is not yet identified.
THE EVOLVING SCIENCE OF ADHD BRAIN CHEMISTRY [https://www.additudemag.com/adhd-brain-science-research/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
EXPANDED NEUROTRANSMITTER FOCUS
While traditional ADHD treatments primarily target dopamine and norepinephrine to improve focus, newer research emphasizes the role of serotonin in regulating emotional dysregulation, anxiety, and sleep. Medications like viloxazine now modulate multiple pathways to address both core ADHD symptoms and co-occurring mood issues.
REWARD PERCEPTION AND MOTIVATION
Stimulants function partly by increasing the perceived reward value of tasks that the brain would otherwise find uninteresting. This shift in perception helps bridge the gap between intention and action. Future medications may target GABA and glutamate pathways to further refine how the brain manages excitatory and inhibitory signals.
HOLISTIC CONNECTIVITY
Treatment is increasingly viewed through a "whole-person" lens, combining medication with lifestyle habits to protect brain connectivity. This approach builds resiliency against secondary complications like chronic insomnia and depression.
ADDRESSING SYSTEMIC BARRIERS IN ADHD ASSESSMENTS [https://www.additudemag.com/adhd-evaluation-inconclusive-race-equity/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
DOCUMENTATION DISPARITIES
Many adults from marginalized communities receive "inconclusive" results because they lack childhood school records. Systemic biases often lead teachers to label impulsivity in minority students as "defiance" rather than a symptom of a neurodevelopmental difference, leaving a trail of disciplinary records instead of diagnostic clues.
CULTURAL MASKING
Strict behavioral expectations or high levels of family support can mask ADHD symptoms during childhood. This "scaffolding" often collapses in adulthood when external structures are removed. Evaluators must look beyond rigid documentation to understand how cultural factors and family routines might have hidden executive dysfunction.
MISDIAGNOSIS RISKS
Because executive dysfunction can mimic mood instability, ADHD is frequently misattributed to anxiety, depression, or bipolar disorder. Equitable assessment requires clinicians to consider how neurodevelopmental struggles manifest across different cultural and social contexts.
EARLY STIMULANT USE LINKED TO REDUCED PSYCHIATRIC RISKS [https://www.additudemag.com/methylphenidate-use-prevents-psychiatric-disorders/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
LONG-TERM PROTECTIVE EFFECTS
Research published in the Journal of Attention Disorders and JAMA Psychiatry indicates that treating ADHD with methylphenidate before age 13 correlates with lower rates of adult psychosis and PTSD. Youth treated with stimulants showed a significantly lower risk of subsequent psychiatric disorders compared to those treated with non-stimulants.
IMPACT ON BRAIN DEVELOPMENT
Longitudinal MRI studies suggest that early stimulant exposure may help normalize atypical brain development, particularly regarding frontal lobe growth. Early intervention aims to address these biological differences before they contribute to secondary emotional dysregulation in adulthood.
CLINICAL SHIFTING
Clinicians often move away from stimulants when PTSD is present due to concerns about hyperarousal. However, the data suggests that consistent early treatment may actually prevent the onset of these secondary conditions by managing the core symptoms that lead to chronic stress and functional impairment.
NAVIGATING COMPLEX CARE WITH A MULTI-SPECIALIST TEAM [https://www.additudemag.com/adhd-child-family-therapists-treatment/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
LAYERED SUPPORT NEEDS
Families managing ADHD often require a diverse team of professionals to address co-occurring conditions. In one documented case, a family employed seven different specialists—including an ADHD assessor, a psychiatrist for medication, and a CBT therapist for trichotillomania—to address evolving challenges like sleep issues and specific phobias.
IMPACT ON FAMILY DYNAMICS
The logistical and emotional demands of managing multiple therapies can place significant strain on caregivers. Recognizing this pressure is essential, as many parents eventually require support, such as couples therapy, to navigate the stress of coordinating intensive neurodevelopmental care.
ESSENTIAL RESOURCES FOR THE POST-DIAGNOSIS JOURNEY [https://hello.autismspeaks.org/c/AQiUuBYQivUKGKfsqoMBIJuV-QEov9aeA1nimWUmEzHcrgTWOFCwDTU29HHv-zm9dfok%5FJM2tmB8]
IMMEDIATE SUPPORT TOOLS
The "100 Day Kit" provides a structured framework for families navigating the first three months following an autism diagnosis. It offers guidance on understanding the diagnosis and identifying initial support services.
CREATING INCLUSIVE CLASSROOMS
The "School Community Tool Kit" contains strategies for educators to build inclusive environments. It focuses on practical methods for supporting students with autism within general education settings to improve both academic and social outcomes.
----------------------------------------
Related links:
* ‘Slightly unhinged’ federal autism meeting portends unclear research priorities [https://www.thetransmitter.org/spectrum/slightly-unhinged-federal-autism-meeting-portends-unclear-research-priorities/?utm_source=The+Transmitter+newsletters&utm_campaign=9182ba8d74-DAILY+20260507+THURSDAY+%28IACC+UNCERTAINTY%29&utm_medium=email&utm_term=0_-434a84391f-448958045]
* Advances in genetic medicine took center stage at INSAR [https://www.thetransmitter.org/spectrum/advances-in-genetic-medicine-took-center-stage-at-insar/?utm_source=The+Transmitter+newsletters&utm_campaign=9182ba8d74-DAILY+20260507+THURSDAY+%28IACC+UNCERTAINTY%29&utm_medium=email&utm_term=0_-434a84391f-448958045]
* 4 Big Insights About ADHD Brain Chemistry [https://www.additudemag.com/adhd-brain-science-research/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
* From ‘Inconclusive’ to Equitable Assessment [https://www.additudemag.com/adhd-evaluation-inconclusive-race-equity/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
* Early Methylphenidate Use May Reduce Risks [https://www.additudemag.com/methylphenidate-use-prevents-psychiatric-disorders/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
* 7 Therapists — and Counting [https://www.additudemag.com/adhd-child-family-therapists-treatment/?ecd=wnl_additude_260507_cons_adhd_treatment&goal=0_d9446392d6-baec4743c2-328240553]
* A Parent's Guide to Autism, The 100 Day Kit, and School Community Tool Kit [https://hello.autismspeaks.org/c/AQiUuBYQivUKGKfsqoMBIJuV-QEov9aeA1nimWUmEzHcrgTWOFCwDTU29HHv-zm9dfok%5FJM2tmB8]